サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423778

進行性多巣性白質脳症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、適応症別、流通チャネル別、地域別

Progressive Multifocal Leukoencephalopathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

出版日
ページ情報
英文 208 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
進行性多巣性白質脳症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、適応症別、流通チャネル別、地域別
出版日: 2024年01月24日
発行: Fairfield Market Research
ページ情報: 英文 208 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の進行性多巣性白質脳症治療の市場規模は、2024年から2031年にかけて着実な成長を遂げると見られています。多くの中低所得国でHIV感染の有病率が上昇していることから、進行性多巣性白質脳症治療の需要が高まると予想されます。血液学的悪性腫瘍の罹患率の増加と進行性多巣性白質脳症の診断が市場拡大の原動力となっています。HIVおよびがん治療に対する好意的な償還政策が、進行性多巣性白質脳症治療市場の成長を刺激すると予想されます。抗レトロウイルス療法や抗ウイルス療法を含む新たな治療オプションの導入は、市場への新規参入者にとって有利な機会を生み出しています。HIVおよび進行性多巣性白質脳症の検査、診断、治療の進歩が、ヘルスケア施設や政府プログラムの改善とともに市場の成長を後押ししています。

北米、次いで欧州が、HIV感染、血液悪性腫瘍、進行性多巣性白質脳症の有病率の上昇に牽引され、進行性多巣性白質脳症治療市場をリードすると予測されています。アジア太平洋市場は、HIV感染率の上昇、HIVおよびがんの治療率の改善、進行性多巣性白質脳症に対する認知度の向上により、継続的な成長が見込まれます。中低所得経済圏における治療受診率の上昇、安全で効果的な治療や正確ながん診断へのアクセスは、進行性多巣性白質脳症の診断増加に寄与すると考えられます。

当レポートでは、世界の進行性多巣性白質脳症治療市場について調査し、市場の概要とともに、薬剤タイプ別、適応症別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の進行性多巣性白質脳症治療市場の見通し、2018年～2031年

  • 世界の進行性多巣性白質脳症治療市場の見通し、薬剤タイプ別、金額（10億米ドル）、2018年～2031年
  • 世界の進行性多巣性白質脳症治療市場の見通し、適応症別、金額（10億米ドル）、2018年～2031年
  • 世界の進行性多巣性白質脳症治療市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界の進行性多巣性白質脳症治療市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の進行性多巣性白質脳症治療市場の見通し、2018年～2031年

第5章 欧州の進行性多巣性白質脳症治療市場の見通し、2018年～2031年

第6章 アジア太平洋の進行性多巣性白質脳症治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの進行性多巣性白質脳症治療市場の見通し、2018年～2031年

第8章 中東・アフリカの進行性多巣性白質脳症治療市場の見通し、2018年～2031年

第9章 競合情勢

  • 薬剤タイプと流通チャネルのヒートマップ
  • メーカーと流通チャネルのヒートマップ
  • 企業の市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer, Inc.
    • F. Hoffman - La Roche Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Sanofi S.A.
    • Allergan plc
    • Novartis AG
    • Mylan N.V.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company

第10章 付録

目次

The global progressive multifocal leukoencephalopathy treatment market is set to experience steady growth from 2024 to 2031. Several key insights are driving this growth in the market:

Factors Driving Market Growth:

  • Rising HIV Prevalence: The growing prevalence of HIV infection in many middle- and low-income countries is expected to fuel the demand for progressive multifocal leukoencephalopathy treatment.
  • Hematological Malignancies: An increasing incidence of hematological malignancies and the diagnosis of progressive multifocal leukoencephalopathy are driving the market's expansion.
  • Favorable Reimbursements: Favorable reimbursement policies for HIV and cancer treatments are expected to stimulate growth in the progressive multifocal leukoencephalopathy treatment market.
  • Emerging Treatment Options: The introduction of emerging treatment options, including anti-retroviral and antiviral therapies, is creating lucrative opportunities for new entrants in the market.
  • Healthcare Infrastructure Improvement: Advances in HIV and progressive multifocal leukoencephalopathy testing, diagnosis, and treatment, along with improved healthcare facilities and government programs, are boosting market growth.

Regional Outlook:

  • North America: North America, followed by Europe, is anticipated to lead the progressive multifocal leukoencephalopathy treatment market, driven by the increasing prevalence of HIV infection, hematological malignancies, and progressive multifocal leukoencephalopathy.
  • Asia-Pacific: The Asia-Pacific market is expected to witness continuous growth due to the rising HIV infection rates, improving treatment rates for HIV and cancer, and increasing awareness about progressive multifocal leukoencephalopathy.
  • Middle East & Africa: Growing treatment-seeking rates in middle- and low-income economies, along with access to safe and effective treatment and accurate cancer diagnosis, will likely contribute to increased progressive multifocal leukoencephalopathy diagnoses.

Opportunities for Growth:

  • Antiviral Agents: The use of antiviral agents, immune response modulators, and immunization treatment for potential progressive multifocal leukoencephalopathy patients is expected to drive market growth.
  • Research and Development: Emphasis on researching and developing drugs and therapies for rare diseases presents a significant opportunity for the progressive multifocal leukoencephalopathy treatment market.
  • Innovative Therapies: Companies are exploring innovative therapies to control JC virus infection rather than improving immunity, which is likely to spur market growth.
  • Improvement in Available Treatments: Leading companies in the progressive multifocal leukoencephalopathy treatment market are focusing on enhancing available treatment options.

Key Players:

Some of the key players in the global progressive multifocal leukoencephalopathy treatment market include Pfizer, Inc., GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc. (Actavis Plc.), Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., and Bristol-Myers Squibb Company, among others.

Table of Contents

1. Executive Summary

  • 1.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Anti-retroviral Therapy
      • 3.1.1.2. Antiviral/Anti JCV
      • 3.1.1.3. Other Symptomatic
  • 3.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. HIV/AIDS
      • 3.2.1.2. Organ Transplantation
      • 3.2.1.3. Multiple Sclerosis
      • 3.2.1.4. Hematological Malignancies
  • 3.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Drug Stores
      • 3.3.1.3. Retail Pharmacies
  • 3.4. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Anti-retroviral Therapy
      • 4.1.1.2. Antiviral/Anti JCV
      • 4.1.1.3. Other Symptomatic
  • 4.2. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. HIV/AIDS
      • 4.2.1.2. Organ Transplantation
      • 4.2.1.3. Multiple Sclerosis
      • 4.2.1.4. Hematological Malignancies
  • 4.3. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Drug Stores
      • 4.3.1.3. Retail Pharmacies
  • 4.4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Anti-retroviral Therapy
      • 5.1.1.2. Antiviral/Anti JCV
      • 5.1.1.3. Other Symptomatic
  • 5.2. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. HIV/AIDS
      • 5.2.1.2. Organ Transplantation
      • 5.2.1.3. Multiple Sclerosis
      • 5.2.1.4. Hematological Malignancies
  • 5.3. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Drug Stores
      • 5.3.1.3. Retail Pharmacies
  • 5.4. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Anti-retroviral Therapy
      • 6.1.1.2. Antiviral/Anti JCV
      • 6.1.1.3. Other Symptomatic
  • 6.2. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. HIV/AIDS
      • 6.2.1.2. Organ Transplantation
      • 6.2.1.3. Multiple Sclerosis
      • 6.2.1.4. Hematological Malignancies
  • 6.3. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Drug Stores
      • 6.3.1.3. Retail Pharmacies
  • 6.4. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Anti-retroviral Therapy
      • 7.1.1.2. Antiviral/Anti JCV
      • 7.1.1.3. Other Symptomatic
  • 7.2. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. HIV/AIDS
      • 7.2.1.2. Organ Transplantation
      • 7.2.1.3. Multiple Sclerosis
      • 7.2.1.4. Hematological Malignancies
  • 7.3. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Drug Stores
      • 7.3.1.3. Retail Pharmacies
  • 7.4. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Anti-retroviral Therapy
      • 8.1.1.2. Antiviral/Anti JCV
      • 8.1.1.3. Other Symptomatic
  • 8.2. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. HIV/AIDS
      • 8.2.1.2. Organ Transplantation
      • 8.2.1.3. Multiple Sclerosis
      • 8.2.1.4. Hematological Malignancies
  • 8.3. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Drug Stores
      • 8.3.1.3. Retail Pharmacies
  • 8.4. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Type vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Drug Type Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. F. Hoffman - La Roche Ltd.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Drug Type Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Gilead Sciences, Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Drug Type Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline plc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Drug Type Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Sanofi S.A.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Drug Type Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Allergan plc
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Drug Type Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Novartis AG
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Drug Type Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Mylan N.V.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Drug Type Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. AbbVie Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Drug Type Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Bristol-Myers Squibb Company
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Drug Type Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations